466 related articles for article (PubMed ID: 17876013)
1. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.
Saltz LB; Lenz HJ; Kindler HL; Hochster HS; Wadler S; Hoff PM; Kemeny NE; Hollywood EM; Gonen M; Quinones M; Morse M; Chen HX
J Clin Oncol; 2007 Oct; 25(29):4557-61. PubMed ID: 17876013
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer.
Larsen FO; Pfeiffer P; Nielsen D; Skougaard K; Qvortrup C; Vistisen K; Fromm AL; Jørgensen TL; Bjerregaard JK; Hoegdall E; Jensen BV
Acta Oncol; 2011 May; 50(4):574-7. PubMed ID: 21529301
[TBL] [Abstract][Full Text] [Related]
3. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
Cunningham D; Humblet Y; Siena S; Khayat D; Bleiberg H; Santoro A; Bets D; Mueser M; Harstrick A; Verslype C; Chau I; Van Cutsem E
N Engl J Med; 2004 Jul; 351(4):337-45. PubMed ID: 15269313
[TBL] [Abstract][Full Text] [Related]
4. Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study).
Zhang W; Azuma M; Lurje G; Gordon MA; Yang D; Pohl A; Ning Y; Bohanes P; Gerger A; Winder T; Hollywood E; Danenberg KD; Saltz L; Lenz HJ
Anticancer Res; 2010 Oct; 30(10):4209-17. PubMed ID: 21036743
[TBL] [Abstract][Full Text] [Related]
5. Integration of novel agents in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
[TBL] [Abstract][Full Text] [Related]
6. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.
Sobrero AF; Maurel J; Fehrenbacher L; Scheithauer W; Abubakr YA; Lutz MP; Vega-Villegas ME; Eng C; Steinhauer EU; Prausova J; Lenz HJ; Borg C; Middleton G; Kröning H; Luppi G; Kisker O; Zubel A; Langer C; Kopit J; Burris HA
J Clin Oncol; 2008 May; 26(14):2311-9. PubMed ID: 18390971
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience.
Gebbia V; Del Prete S; Borsellino N; Ferraù F; Tralongo P; Verderame F; Leonardi V; Capasso E; Maiello E; Bordonaro R; Stinco S; Agostara B; Barone C
Clin Colorectal Cancer; 2006 Mar; 5(6):422-8. PubMed ID: 16635281
[TBL] [Abstract][Full Text] [Related]
8. Multicenter Phase II study of cetuximab plus irinotecan in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines.
Tahara M; Shirao K; Boku N; Yamaguchi K; Komatsu Y; Inaba Y; Arai T; Mizunuma N; Satoh T; Takiuchi H; Nishina T; Sakata Y
Jpn J Clin Oncol; 2008 Nov; 38(11):762-9. PubMed ID: 18836202
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of cetuximab/irinotecan in patients with heavily pretreated metastatic colorectal cancer: predictive value of early specific toxicities.
Gamucci T; Nelli F; Cianci G; Grassi G; Moscetti L; Sperduti I; Zeuli M; Cortesi E; D'Auria G; Pollera CF
Clin Colorectal Cancer; 2008 Jul; 7(4):273-9. PubMed ID: 18650196
[TBL] [Abstract][Full Text] [Related]
10. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Heinemann V; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Müller S; Link H; Niederle N; Rost A; Höffkes HG; Moehler M; Lindig RU; Modest DP; Rossius L; Kirchner T; Jung A; Stintzing S
Lancet Oncol; 2014 Sep; 15(10):1065-75. PubMed ID: 25088940
[TBL] [Abstract][Full Text] [Related]
11. Cetuximab Plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan: the LABEL study.
Buzaid AC; Mathias Cde C; Perazzo F; Simon SD; Fein L; Hidalgo J; Murad AM; Esser R; Senger S; Lerzo G
Clin Colorectal Cancer; 2010 Dec; 9(5):282-9. PubMed ID: 21208842
[TBL] [Abstract][Full Text] [Related]
12. Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy.
Scartozzi M; Bearzi I; Pierantoni C; Mandolesi A; Loupakis F; Zaniboni A; Catalano V; Quadri A; Zorzi F; Berardi R; Biscotti T; Labianca R; Falcone A; Cascinu S
J Clin Oncol; 2007 Sep; 25(25):3930-5. PubMed ID: 17761976
[TBL] [Abstract][Full Text] [Related]
13. Treatment with cetuximab, bevacizumab and irinotecan in heavily pretreated patients with metastasized colorectal cancer.
Halama N; Herrmann C; Jaeger D; Herrmann T
Anticancer Res; 2008; 28(6B):4111-5. PubMed ID: 19192669
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer.
Garrett CR; Bekaii-Saab TS; Ryan T; Fisher GA; Clive S; Kavan P; Shacham-Shmueli E; Buchbinder A; Goldberg RM
Cancer; 2013 Dec; 119(24):4223-30. PubMed ID: 24105075
[TBL] [Abstract][Full Text] [Related]
15. Irinotecan-cetuximab-bevacizumab as a salvage treatment in heavily pretreated metastatic colorectal cancer patients: a retrospective observational study.
Feliu Batlle J; Cuadrado E; Castro J; Caldés T; Belda C; Sastre J; Barriuso J; Martínez Marín V; Díaz-Rubio E; González-Barón M
Chemotherapy; 2011; 57(2):138-44. PubMed ID: 21447947
[TBL] [Abstract][Full Text] [Related]
16. Dual Inhibition of EGFR and VEGF in Heavily Pretreated Patients with Metastatic Colorectal Cancer.
Larsen FO; Markussen A; Nielsen D; Colville-Ebeling B; Riis LB; Jensen BV
Oncology; 2017; 93(3):191-196. PubMed ID: 28531891
[TBL] [Abstract][Full Text] [Related]
17. Irinotecan associated with cetuximab given every 2 weeks versus cetuximab weekly in metastatic colorectal cancer.
Mrabti H; De la Fouchardiere C; Desseigne F; Dussart S; Negrier S; Errihani H
J Cancer Res Ther; 2009; 5(4):272-6. PubMed ID: 20160361
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study.
Wilke H; Glynne-Jones R; Thaler J; Adenis A; Preusser P; Aguilar EA; Aapro MS; Esser R; Loos AH; Siena S
J Clin Oncol; 2008 Nov; 26(33):5335-43. PubMed ID: 18854570
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancer.
Carneiro BA; Ramanathan RK; Fakih MG; Krishnamurthi SS; Lembersky BC; Stoller RG; Lancaster SL; Pinkerton RA; Crandall TL; Schmotzer AR; Potter DM; Bahary N
Clin Colorectal Cancer; 2012 Mar; 11(1):53-9. PubMed ID: 21813336
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of high-dose cetuximab plus irinotecan in colorectal cancer patients with KRAS wild-type tumors who progressed after standard dose of cetuximab plus irinotecan.
Fora AA; McMahon JA; Wilding G; Groman A; Ma WW; Romano KS; Fakih MG
Oncology; 2013; 84(4):210-3. PubMed ID: 23328486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
